Trastuzumab

Trastuzumab - most related articles:

- Neratinib shows promise in trastuzumab resistant breast cancer - 5.5
- Lower heart effects from Herceptin breast cancer treatment with chemotherapy - 5.3
- Tykerb with Herceptin increases advanced breast cancer survival - 4.8
- Triple drug combination promising to treat breast cancer - 3.9

Trastuzumab articles

Tykerb with Herceptin increases advanced breast cancer survival
An investigational combination of TYKERB (lapatinib) plus HERCEPTIN (trastuzumab) proved a median survival of 14 months in women with an aggressive form of breast cancer.

Neratinib shows promise in trastuzumab resistant breast cancer
Fox Chase Cancer Center researchers report that a combination of trastuzumab and neratinib (HKI-272) a novel small molecule inhibitor of the HER2 receptor (ErbB2) appears active in women with HER2-positive metastatic breast cancer who have progressed on previous trastuzumab based therapies.

Triple drug combination promising to treat breast cancer
Combining two chemotherapy drugs with trastuzumab (Herceptin) to treat women who have metastatic HER2+ breast cancer may offer physicians another choice in their treatment options.

SPOT-Light HER2 CISH kit approved for breast cancer patients
SPOT-Light HER2 CISH kit - a novel genetic test for determining whether patients with breast cancer are good candidates for treatment with the drug Herceptin (trastuzumab) has been approved by the U.S. Food and Drug Administration.

Lower heart effects from Herceptin breast cancer treatment with chemotherapy
A new pilot study by investigators at Memorial Sloan-Kettering Cancer Center (MSKCC) found that breast cancer patients can be treated safely with a "dose-dense" regimen of standard chemotherapy agents and the antibody trastuzumab (Herceptin), a drug that has previously been shown to cause cardiac toxicity.

5 Trastuzumab articles listed above.

List health news, Health organizations, Health news world, Glossary, Best health articles, Featured     Go to top

The information provided on Health Newstrack is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. We comply with the HONcode principles for trustworthy health information, and Health News Track is hon code accredited, verify here.
About us, Site map Privacy policy, Disclaimer
© 2007, 2008, 2009, 2010, 2011 HealthNewsTrack.com
11.16